FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092151721> ?p ?o ?g. }

• W2092151721 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCOverexpression of EGFR has been identified as a negative prognostic factor in squamous cell carcinoma of the head and neck (SCCHN). Patients with SCCHN who respond to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop acquired resistance. Colocalization of EGFR expression and tumor hypoxia in SCCHN is associated with poor outcome, suggesting a role for hypoxia in drug resistance. Non-invasive imaging strategies to accurately identify and monitor patients whose tumors have become resistant to EGFR-TKI therapy would have clinical value. As part of a pre-clinical multiparametric imaging study, we have investigated EGFR-TKI resistance using intrinsic susceptibility magnetic resonance imaging (IS-MRI), which relies on the dependence of the MRI transverse relaxation rate R2* on the ratio of oxy- to deoxyhemoglobin in blood. Given its relationship to blood oxygen saturation and pO2 in and around blood vessels, R2* and hyperoxia-induced ΔR2* are being investigated as imaging biomarkers of tumor oxygenation.IS-MRI was performed on size-matched xenografts derived from the EGFR TKI sensitive SCCHN cell line CAL27 and an isogenic subline resistant to multiple TKIs (gefitinib, erlotinib, and afatinib). Tumor-bearing mice were administered the hypoxia marker pimonidazole, and baseline R2* quantified from resistant (n=8) or sensitive (n=7) tumors whilst the host breathed air. Gas delivery was then switched to 100% O2, and tumour R2* measured again. Finally, mice were administered the perfusion marker Hoechst 33342. The extent of functional tumor vasculature and hypoxia were quantified ex vivo using fluorescence microscopy. Resistant tumors revealed regions of fast R2* (functional, deoxygenated vasculature) restricted primarily to the tumor periphery, while sensitive tumors exhibited a more heterogeneous distribution of fast R2* throughout. There was no significant difference in baseline R2* between the two cohorts (64 ± 4s-1 and 76 ± 5s-1, p=0.07). Hyperoxia resulted in a significantly smaller ΔR2* in the resistant tumors (-2.4 ± 1.4s-1) compared to sensitive tumors (-9.1 ± 2s-1, p<0.05). Resistant tumors had significantly lower Hoechst 33342 uptake (9.5 ± 1.3%, p<0.01) and increased pimonidazole adducts (21 ± 2%, p<0.01) compared to sensitive tumors (19.2 ± 3% and 10.4 ± 2% respectively). Tumor regions of fast R2* and hyperoxic-induced ΔR2* were spatially associated with Hoechst 33342 uptake.Tumors with resistance to EGFR-TKIs exhibited a reduced hemodynamic MRI response that was associated with decreased vessel perfusion and increased tumor hypoxia. IS-MRI informs on phenotypic differences in tumor blood vessel distribution, functionality and oxygenation associated with EGFR-TKI resistance and sensitivity, affording useful non-invasive imaging biomarkers for investigating EGFR drug resistance and tumor hypoxia.Citation Format: Lauren CJ Baker, Carol Box, Arti Sikka, Gary Box, Suzanne A. Eccles, Simon P. Robinson. Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human squamous cell carcinoma of the head and neck (SCCHN). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4459. doi:10.1158/1538-7445.AM2013-4459" @default.
• W2092151721 created "2016-06-24" @default.
• W2092151721 creator A5025972115 @default.
• W2092151721 creator A5027037729 @default.
• W2092151721 creator A5044776185 @default.
• W2092151721 creator A5051107742 @default.
• W2092151721 creator A5063250722 @default.
• W2092151721 creator A5070692678 @default.
• W2092151721 date "2013-04-15" @default.
• W2092151721 modified "2023-09-25" @default.
• W2092151721 title "Abstract 4459: Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human squamous cell carcinoma of the head and neck (SCCHN)." @default.
• W2092151721 doi "https://doi.org/10.1158/1538-7445.am2013-4459" @default.
• W2092151721 hasPublicationYear "2013" @default.
• W2092151721 type Work @default.
• W2092151721 sameAs 2092151721 @default.
• W2092151721 citedByCount "2" @default.
• W2092151721 countsByYear W20921517212018 @default.
• W2092151721 crossrefType "proceedings-article" @default.
• W2092151721 hasAuthorship W2092151721A5025972115 @default.
• W2092151721 hasAuthorship W2092151721A5027037729 @default.
• W2092151721 hasAuthorship W2092151721A5044776185 @default.
• W2092151721 hasAuthorship W2092151721A5051107742 @default.
• W2092151721 hasAuthorship W2092151721A5063250722 @default.
• W2092151721 hasAuthorship W2092151721A5070692678 @default.
• W2092151721 hasConcept C121608353 @default.
• W2092151721 hasConcept C126322002 @default.
• W2092151721 hasConcept C142724271 @default.
• W2092151721 hasConcept C143998085 @default.
• W2092151721 hasConcept C178790620 @default.
• W2092151721 hasConcept C185592680 @default.
• W2092151721 hasConcept C2778087573 @default.
• W2092151721 hasConcept C2779081379 @default.
• W2092151721 hasConcept C2779438470 @default.
• W2092151721 hasConcept C2780580887 @default.
• W2092151721 hasConcept C2780586478 @default.
• W2092151721 hasConcept C502942594 @default.
• W2092151721 hasConcept C509974204 @default.
• W2092151721 hasConcept C540031477 @default.
• W2092151721 hasConcept C71924100 @default.
• W2092151721 hasConcept C7836513 @default.
• W2092151721 hasConceptScore W2092151721C121608353 @default.
• W2092151721 hasConceptScore W2092151721C126322002 @default.
• W2092151721 hasConceptScore W2092151721C142724271 @default.
• W2092151721 hasConceptScore W2092151721C143998085 @default.
• W2092151721 hasConceptScore W2092151721C178790620 @default.
• W2092151721 hasConceptScore W2092151721C185592680 @default.
• W2092151721 hasConceptScore W2092151721C2778087573 @default.
• W2092151721 hasConceptScore W2092151721C2779081379 @default.
• W2092151721 hasConceptScore W2092151721C2779438470 @default.
• W2092151721 hasConceptScore W2092151721C2780580887 @default.
• W2092151721 hasConceptScore W2092151721C2780586478 @default.
• W2092151721 hasConceptScore W2092151721C502942594 @default.
• W2092151721 hasConceptScore W2092151721C509974204 @default.
• W2092151721 hasConceptScore W2092151721C540031477 @default.
• W2092151721 hasConceptScore W2092151721C71924100 @default.
• W2092151721 hasConceptScore W2092151721C7836513 @default.
• W2092151721 hasLocation W20921517211 @default.
• W2092151721 hasOpenAccess W2092151721 @default.
• W2092151721 hasPrimaryLocation W20921517211 @default.
• W2092151721 hasRelatedWork W1979045914 @default.
• W2092151721 hasRelatedWork W1990608579 @default.
• W2092151721 hasRelatedWork W1995793475 @default.
• W2092151721 hasRelatedWork W2009292054 @default.
• W2092151721 hasRelatedWork W2058118219 @default.
• W2092151721 hasRelatedWork W2069252307 @default.
• W2092151721 hasRelatedWork W2111338936 @default.
• W2092151721 hasRelatedWork W2158453396 @default.
• W2092151721 hasRelatedWork W2266347788 @default.
• W2092151721 hasRelatedWork W2291585432 @default.
• W2092151721 hasRelatedWork W2332119077 @default.
• W2092151721 hasRelatedWork W2589106419 @default.
• W2092151721 hasRelatedWork W2612717375 @default.
• W2092151721 hasRelatedWork W2752953293 @default.
• W2092151721 hasRelatedWork W2803728085 @default.
• W2092151721 hasRelatedWork W2820861841 @default.
• W2092151721 hasRelatedWork W2897817143 @default.
• W2092151721 hasRelatedWork W2972003353 @default.
• W2092151721 hasRelatedWork W2980770048 @default.
• W2092151721 hasRelatedWork W3000415041 @default.
• W2092151721 isParatext "false" @default.
• W2092151721 isRetracted "false" @default.
• W2092151721 magId "2092151721" @default.
• W2092151721 workType "article" @default.